Results of the ZUMA-1 Trial Exploring KTE-C19 in NHL

Video

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC

Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC

Jordyn Sava
July 8th 2025
Article

Read More

Exploring Innovations in Lymphoma Treatment With Russler-Germain

Exploring Innovations in Lymphoma Treatment With Russler-Germain

Jordyn Sava;David A. Russler-Germain, MD, PhD
February 27th 2025
Podcast

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Listen

Luspatercept’s Benefit in MDS: Dr Garcia-Manero on COMMANDS Trial

Luspatercept’s Benefit in MDS: Dr Garcia-Manero on COMMANDS Trial

Jordyn Sava
July 7th 2025
Article

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Nichole Tucker
July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Jordyn Sava
July 4th 2025
Article

Read More

Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification

Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification

Jordyn Sava
July 3rd 2025
Article

Read More